ARTICLE | Company News
Keryx seeks U.S. approval for Zerenex
August 9, 2013 12:53 AM UTC
Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) submitted an NDA to FDA for Zerenex ferric citrate to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. By year end, the company also plans to submit an MAA to EMA for the oral ferric iron-based phosphate binder. Keryx has worldwide rights to Zerenex, including Japan but excluding the rest of the Asia Pacific region, from Panion & BF Biotech Inc. (Taipei, Taiwan). ...